Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …

All patients with venous thromboembolism (VTE) should receive anticoagulant treatment in
the absence of absolute contraindications. Initial anticoagulant treatment is crucial for …

Both apixaban and rivaroxaban have been approved for use in acute venous
thromboembolism (VTE). Although indirect comparison through network meta-analyses of …

To provide direct comparison between apixaban and rivaroxaban in patients with acute
cancer‐associated venous thromboembolism (Ca‐VTE), consecutive patients treated with …

Objective To compare the bleeding risk in patients with gastrointestinal (GI) cancer with that
in patients with non-GI cancer treated with anticoagulation for acute cancer-associated …

Background Cancer‐associated venous thromboembolism (VTE) carries a high rate of
recurrence and death. Guidelines recommend continued anticoagulation therapy as long as …

Background Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban
are preferred over vitamin K antagonists for the treatment of venous thromboembolism …

Background Although several studies have compared the effectiveness and safety of
rivaroxaban and apixaban in patients with venous thromboembolism (VTE), direct …

Randomized controlled trials leading to the approval of apixaban and rivaroxaban for
venous thromboembolism (VTE) did not include patients with upper extremity deep vein …

Objectives To investigate the association of extremes in bodyweight (EBW) and outcomes in
patients with acute venous thromboembolism (VTE). Recurrent VTE, major bleeding, and …